欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2021, Vol. 26 ›› Issue (2): 144-153.doi: 10.12092/j.issn.1009-2501.2021.02.004

• 基础研究 • 上一篇    下一篇

瑞舒伐他汀通过UCP2-SIRT3信号调控脑I/R对神经元的损伤

云强1,董雪佳2,王梦娇2,刘雅虹2,王智光3,江名芳3   

  1. 1内蒙古自治区人民医院神经外科,呼和浩特市 010020,内蒙古;2内蒙古医科大学研究生院,呼和浩特市 010058,内蒙古;3内蒙古医科大学附属医院神经内科,呼和浩特市 010059,内蒙古
  • 收稿日期:2020-07-13 修回日期:2020-09-06 出版日期:2021-02-26 发布日期:2021-03-04
  • 通讯作者: 江名芳,女,博士,主任医师,教授,硕士生导师,研究方向:脑血管病、帕金森病、头面痛。 Tel: 15335553745 E-mail: mingfang-j@163.com
  • 作者简介:云强,男,博士,主任医师,硕士生导师,研究方向:脑血管病。 Tel: 18047194223 E-mail: nmyunqiang@126.com
  • 基金资助:
    内蒙古自治区科技计划项目(201702144);内蒙古医科大学附属医院博士启动金项目(NYFY BS 2018);内蒙古自然科学基金面上项目(2020MS08197);内蒙古自治区自然科学基金项目(2018LH08012)

Rosuvastatin regulates cerebral I/R damage to neurons by UCP2-SIRT3 signal

YUN Qiang 1, DONG Xuejia 2, WANG Mengjiao 2, LIU Yahong 2, WANG Zhiguang 3, JIANG Mingfang 3   

  1. 1 Department of Neurosurgery, People's Hospital of Inner Mongolia Autonomous Region, Hohhot 010020, Inner Mongolia, China; 2 Graduate School of Inner Mongolia Medical University, Hohhot 010058, Inner Mongolia, China; 3 Department of Neurology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010059, Inner Mongolia, China

  • Received:2020-07-13 Revised:2020-09-06 Online:2021-02-26 Published:2021-03-04

摘要: 目的:研究瑞舒伐他汀对脑缺血-再灌注损伤的保护作用及作用机制。方法:(1)建立脑梗死及OGD/R细胞模型,检测不同浓度瑞舒伐他汀对细胞增殖及细胞凋亡的影响;(2)用不同浓度瑞舒伐他汀处理OGD/R细胞模型,观察瑞舒伐他汀对细胞形态和细胞中UCP2/SIRT3表达和定位的影响;(3)构建UCP2沉默的细胞系,观察细胞线粒体形态和细胞中TOMM20及SIRT3分子表达与定位,研究瑞舒伐他汀在OGD/R细胞模型中发挥保护作用的通道和机制;(4)检测线粒体膜电位,PCR检测线粒体生成基因PGC1、Drp1和Opa1表达,研究瑞舒伐他汀对线粒体的保护作用。结果:(1)不同浓度瑞舒伐他汀均可以明显减低OGD/R细胞凋亡,提高细胞存活率;(2)瑞舒伐他汀通过影响细胞UCP2和SIRT3表达,进而发挥细胞保护作用,使细胞免受OGD/R损伤;(3)瑞舒伐他汀通过调控UCP2影响TOMM20表达,增加线粒体跨膜转运和能量代谢,增强线粒体功能,提高细胞存活;(4)瑞舒伐他汀阻止OGD/R细胞膜电位下降,保护线粒体,改善细胞状态,减少细胞凋亡。 结论:瑞舒伐他汀通过调控UCP2/SIRT通路来抑制OGD/R细胞线粒体损伤,从而发挥神经元保护作用。

关键词: 瑞舒伐他汀, UCP2, SIRT3, OGD/R, 缺血再灌注

Abstract: AIM: To study the protective effect and mechanism of rosuvastatin on cerebral ischemia-reperfusion injury.  METHODS: (1) Cerebral infarction and OGD/R cell models were established to detect the effects of different concentrations of rosuvastatin on cell proliferation and apoptosis; (2) Different concentrations of rosuvastatin were used to treat OGD/R cell models and to observe rosuvastatin effects on cell morphology and expression and localization of UCP2-SIRT3 in cells; (3) UCP2 silent cell line was constructed to observe cell mitochondrial morphology and expression and localization of TOMM20 and SIRT3 molecules in cells, and to study the channels and mechanisms that play a protective role of rosuvastatin in OGD/R cell model; (4) The mitochondrial membrane potential, mitochondrial gene PGC1, Drp1 and Opa1 expression were detected to study the protective effect of rosuvastatin on mitochondria. RESULTS: (1) Rosuvastatin of different concentrations could significantly reduce OGD/R cell apoptosis and increase cell survival rate; (2) Rosuvastatin exerted cell protection by affecting the expression of UCP2 and SIRT3 in cells, thereby protecting cells from OGD/R injury; (3) Rosuvastatin affected the expression of TOMM20 by regulating UCP2, increased mitochondrial transmembrane transport and energy metabolism, enhanced mitochondrial function, and improved cell state and reduced apoptosis. CONCLUSION: Rosuvastatin inhibits mitochondrial damage of OGD/R cells by regulating UCP2/SIRT pathway, thereby exerting neuron protection.

Key words: rosuvastatin, UCP2, SIRT3, OGD/R, ischemia-reperfusion

中图分类号: